Wanted pages
From Glioblastoma Treatments
Jump to navigationJump to search
List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.
Showing below up to 50 results in range #1 to #50.
- Not specified (82 links)
- 3 (56 links)
- 4 (43 links)
- 2 (40 links)
- 1 (19 links)
- Property:Has Toxicity Level (14 links)
- Property:Has Usefulness Rating (14 links)
- Property:Has treatment name (13 links)
- Not rated (9 links)
- 2.5 (6 links)
- Property:Has OS with (6 links)
- Property:Has OS without (6 links)
- Property:Has PFS with (6 links)
- Property:Has PFS without (6 links)
- " in your query was not closed by a matching " (4 links)
- 5 (4 links)
- Cannabis and Cannabis-derived Products (e.g., Sativex) (4 links)
- Comparable to standard TMZ treatments, but timing affects management of side effects. (4 links)
- Ellagic Acid (4 links)
- Fish Oil (Omega-3 Fatty Acids: EPA and DHA) (4 links)
- Garlic (Allium sativum) (4 links)
- Not applicable (4 links)
- Sativex (Nabiximols) (4 links)
- 3.5 (3 links)
- 3 - Under investigation (3 links)
- 6.1 months for all patients, 5.9 months for EGFR amplified patients (3 links)
- CBD (Cannabidiol) (3 links)
- Cannabigerol (CBG) (3 links)
- Celebrex (Celecoxib) and Other NSAIDs (3 links)
- Chronotherapy with Temozolomide (TMZ) (3 links)
- Combination of Repurposed Drugs plus Temodar (3 links)
- Data not specified (3 links)
- Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival (3 links)
- Disulfiram (Antabuse) (3 links)
- Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months (3 links)
- ICT-107 has demonstrated potential in extending progression-free and overall survival in GBM patients, especially in specific subgroups. Its ability to target multiple tumor-associated antigens may offer a broader immunogenic response. (3 links)
- Isotretinoin (Accutane) (3 links)
- Keppra (Levetiracetam) (3 links)
- MN-166 (Ibudilast) (3 links)
- Methadone (D,L-methadone) (3 links)
- Not applicable; studies focusing on PFS-6 as a primary endpoint (3 links)
- Not reached at a median follow-up of 5.8 months (3 links)
- Not specified in the provided text (3 links)
- PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR (3 links)
- Phase II (3 links)
- Proton Beam Therapy (PBT) (3 links)
- Proton Pump Inhibitors (e.g., Lansoprazole, Nexium) (3 links)
- Sodium R Lipoate and Hydroxycitrate (METABLOC) (3 links)
- Temozolomide (TMZ) (3 links)
- The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone (3 links)
